title: MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas.
abstract: OBJECTIVE
  We performed a prospective study using magnetic resonance imaging (MRI) at regular post-operative intervals in non-irradiated patients with non-functioning pituitary adenomas (NFAs) to assess the frequency of tumoral regrowth and recurrences, in order to define the indications of post-operative radiotherapy.
  
  
  METHODS
  Fifty-one patients aged 25--80 years (mean, 55.6plus minus12.3 years) were included. Post-operative MRIs were performed 3--12 months (mean, 5.2plus minus1.7 months) after surgery, 6 months later and then, every 12--18 months for at least 2 years. The mean post-operative follow-up was 67.7plus minus31.8 months (range, 24--144 months).
  
  
  RESULTS
  In 17 patients (33%, group I) no tumoral residue was observed on post-operative MRIs and no tumoral recurrence was diagnosed. Tumour regrowth was detected in 13 of the 34 patients (38.2%) with post-operative tumoral residue (group II), 7--66 months (mean, 27.3plus minus17.3 months) after surgery. In this group, Kaplan--Meier analysis showed 78.8% recurrence free survival at 2 years and 60.9% at 5 years. Patients with tumoral regrowth had higher mean residual tumoral volume than patients without any tumoral regrowth in the group II (258plus minus165 vs 163plus minus165 mm(3), P=0.05).
  
  
  CONCLUSIONS
  We suggest a MRI protocol that includes, a 4- to 6-, 12- and 24-month post-operative MRI for every patient. When no tumoral residue is seen, pituitary radiotherapy is useless. MRI must be repeated 3, 5 and 10 years after surgery to eliminate late recurrence. The observed frequency of tumoral regrowth in patients with tumoral residue does not justify systematic post-operative radiotherapy. It should be performed only when tumoral regrowth is proved by a yearly MRI survey.
authors.affiliation: Department of Neuroradiology, Hopital Roger Salengro, Chru Lille, France. gsotoares@chru-lille.fr
authors.forename: Gustavo
authors.initials: G
authors.lastname: Soto-Ares
authors.forename: Christine
authors.initials: C
authors.lastname: Cortet-Rudelli
authors.forename: Richard
authors.initials: R
authors.lastname: Assaker
authors.forename: Arnaud
authors.initials: A
authors.lastname: Boulinguez
authors.forename: C
authors.initials: C
authors.lastname: Dubest
authors.forename: Didier
authors.initials: D
authors.lastname: Dewailly
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Pruvo
mesh_terms: D000236:Adenoma / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D010911:Pituitary Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D011182:Postoperative Care; D011446:Prospective Studies; D011878:Radiotherapy